SQZ Biotechnologies Company SQZ
Day range unavailable
52-week range unavailable
- Market cap
- 12.83M
- Revenue (ttm)
- 18.61M
- Shares out
- 29.49M
- Forward P/E
- -0.62
- Beta
- 2.71
- Analysts
- Buy
- Price target
- 19.00 (+4267.8%)
- Earnings date
- Aug 3, 2023
Key statistics
- Enterprise value
- -6.50M
- PEG ratio
- 0.00
- Price / sales
- 0.69
- Price / book
- 0.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -37.69M
- Total cash
- 39.87M
- Total debt
- 24.50M
- Return on equity
- -104.93%
- Short % of float
- 3.03%
- 50-day average
- 0.509346
- 200-day average
- 1.13
Analyst view
Consensus: buy
- Target (low)
- 4.00
- Target (mean)
- 19.00
- Target (high)
- 34.00
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 3, 2023
Expected Aug 3, 2023. Consensus EPS estimate -0.60.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 3, 2023 | Jun 1, 2023 | -0.60 | — | — | — |
| May 10, 2023 | Mar 1, 2023 | -0.54 | — | — | — |
| Mar 22, 2023 | Dec 1, 2022 | -0.80 | — | — | — |
| Nov 9, 2022 | Sep 1, 2022 | -0.89 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.79 | — | — | — |
| May 10, 2022 | Mar 1, 2022 | -0.71 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Dec 1, 2022 | Chardan Capital | main | — | Buy |
| Dec 1, 2022 | B of A Securities | down | Buy | Underperform |
| Nov 10, 2022 | Chardan Capital | main | — | Buy |
| Oct 20, 2022 | HC Wainwright & Co. | init | — | Buy |
| Oct 6, 2022 | BTIG | main | — | Buy |
About SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sqzbiotech.com
News
Serica Energy cuts 2026 production guidance as brokers retain 'buy' ratings 
Serica Energy maintains cash flow guidance despite Triton delay 
Serica Energy gets Jefferies 'buy' rating and 320p price target 
Reviewing Galectin Therapeutics (NASDAQ:GALT) & SQZ Biotechnologies (NYSE:SQZ) 
Serica Energy says it won't raise bid for Pharos 
Serica Energy shares rise on bond financing talk 
Financial Comparison: SQZ Biotechnologies (NYSE:SQZ) vs. Cortexyme (NASDAQ:CRTX) 
Cortexyme (NASDAQ:CRTX) and SQZ Biotechnologies (NYSE:SQZ) Critical Review 
Head to Head Contrast: NKGen Biotech (NYSE:NKGN) and SQZ Biotechnologies (NYSE:SQZ) 
Head to Head Comparison: NKGen Biotech (NYSE:NKGN) versus SQZ Biotechnologies (NYSE:SQZ)
Your note
Sign in to keep a note on SQZ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARMON R. SHAREI IRREVOCABLE GST TRUST OF 2016 | Trustee | Conversion of Exercise of derivative security | Nov 2, 2020 | 385,891 |
| CAPASSO RICHARD | Officer | Sale | Aug 14, 2022 | 0 |
| INVUS PUBLIC EQUITIES ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 2, 2020 | 0 |
| JENSEN KLAVS F. PH.D. | Director | Purchase | May 24, 2022 | 353,309 |
| KNOPF LAWRENCE J | General Counsel | Stock Award(Grant) | Jun 29, 2022 | 1,938 |
| POLARIS MANAGEMENT CO. VII, L.L.C | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 2, 2020 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Temasek Holdings (Private) Limited | 9.35% | 2,758,169 | 1.20M | Mar 30, 2023 |
| American International Group, Inc. | 8.54% | 2,517,173 | 1.09M | Mar 30, 2023 |
| Artal Group S.A. | 5.45% | 1,606,309 | 698.74K | Mar 30, 2023 |
| Maverick Capital Ltd. | 3.57% | 1,051,771 | 457.52K | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 3.19% | 941,752 | 409.66K | Mar 30, 2023 |
| Stifel Financial Corporation | 2.96% | 874,326 | 380.33K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.23% | 657,886 | 286.18K | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 0.82% | 241,040 | 104.85K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.28% | 83,721 | 36.42K | Feb 27, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.21% | 62,400 | 27.14K | Dec 30, 2022 |
| iShares Micro Cap ETF | 0.18% | 53,703 | 23.36K | Feb 27, 2023 |
| Vanguard Balanced Index Fund | 0.07% | 21,128 | 9.19K | Dec 30, 2022 |